Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Chemical denaturation as a tool in the formulation optimization of biologics.

Freire E, Schön A, Hutchins BM, Brown RK.

Drug Discov Today. 2013 Oct;18(19-20):1007-13. doi: 10.1016/j.drudis.2013.06.005. Epub 2013 Jun 21. Review.

2.

Conformational stability and self-association equilibrium in biologics.

Clarkson BR, Schön A, Freire E.

Drug Discov Today. 2016 Feb;21(2):342-7. doi: 10.1016/j.drudis.2015.11.007. Epub 2015 Nov 19. Review.

3.

Changing role of formulation in biologics drug development.

Saylor T.

Drug Discov Today. 2014 Aug;19(8):1031-2. doi: 10.1016/j.drudis.2014.04.019. Epub 2014 May 6. No abstract available.

PMID:
24815923
4.

Reversible denaturation of oligomeric human chaperonin 10: denatured state depends on chemical denaturant.

Guidry JJ, Moczygemba CK, Steede NK, Landry SJ, Wittung-Stafshede P.

Protein Sci. 2000 Nov;9(11):2109-17. Erratum in: Protein Sci 2000 Dec;9(12):2583.

5.

Influence of urea and guanidine hydrochloride on lysozyme stability and thermal denaturation; a correlation between activity, protein dynamics and conformational changes.

Hédoux A, Krenzlin S, Paccou L, Guinet Y, Flament MP, Siepmann J.

Phys Chem Chem Phys. 2010 Oct 28;12(40):13189-96. doi: 10.1039/c0cp00602e. Epub 2010 Aug 31.

PMID:
20820578
6.

Equilibrium unfolding of RNase Rs from Rhizopus stolonifer: pH dependence of chemical and thermal denaturation.

Deshpande RA, Khan MI, Shankar V.

Biochim Biophys Acta. 2003 May 30;1648(1-2):184-94.

PMID:
12758161
7.
8.

The stability factor: importance in formulation development.

Krishnamurthy R, Manning MC.

Curr Pharm Biotechnol. 2002 Dec;3(4):361-71. Review.

PMID:
12463418
10.

Isothermal chemical denaturation as a complementary tool to overcome limitations of thermal differential scanning fluorimetry in predicting physical stability of protein formulations.

Svilenov H, Markoja U, Winter G.

Eur J Pharm Biopharm. 2018 Apr;125:106-113. doi: 10.1016/j.ejpb.2018.01.004. Epub 2018 Jan 9.

11.

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.

Strohl WR.

BioDrugs. 2015 Aug;29(4):215-39. doi: 10.1007/s40259-015-0133-6. Review.

12.

Early development of therapeutic biologics--pharmacokinetics.

Baumann A.

Curr Drug Metab. 2006 Jan;7(1):15-21. Review.

PMID:
16454690
13.

pH dependence of the stability of barstar to chemical and thermal denaturation.

Khurana R, Hate AT, Nath U, Udgaonkar JB.

Protein Sci. 1995 Jun;4(6):1133-44.

14.

Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.

Brader ML, Estey T, Bai S, Alston RW, Lucas KK, Lantz S, Landsman P, Maloney KM.

Mol Pharm. 2015 Apr 6;12(4):1005-17. doi: 10.1021/mp400666b. Epub 2015 Feb 27.

PMID:
25687223
15.

Lyophilization and development of solid protein pharmaceuticals.

Wang W.

Int J Pharm. 2000 Aug 10;203(1-2):1-60. Review.

PMID:
10967427
19.

Reversible thermal denaturation of human FGF-1 induced by low concentrations of guanidine hydrochloride.

Blaber SI, Culajay JF, Khurana A, Blaber M.

Biophys J. 1999 Jul;77(1):470-7.

20.

Denaturing action of urea and guanidine hydrochloride towards two thermophilic esterases.

Del Vecchio P, Graziano G, Granata V, Barone G, Mandrich L, Rossi M, Manco G.

Biochem J. 2002 Nov 1;367(Pt 3):857-63.

Supplemental Content

Support Center